Search Results - "Lindley, Celeste M"

Validation of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 Catalytic Activity by FAUCETTE, Stephanie R, HAWKE, Roy L, LECLUYSE, Edward L, SHORD, Stacy S, BINGFANG YAN, LAETHEM, Ronald M, LINDLEY, Celeste M

“…The purpose of this study was to establish bupropion (BUP) hydroxylation as a selective in vitro marker of cytochrome P450 (CYP) 2B6 catalytic activity. Among…”
Get full text

Nelarabine: A novel purine antimetabolite antineoplastic agent by Buie, Larry W., PharmD, Epstein, Stacy S., PharmD, Lindley, Celeste M., PharmD

“…Abstract Background: Nelarabine was approved by the US Food and Drug Administration (FDA) in October 2005 for the treatment of T-cell acute lymphoblastic…”
Get full text

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa by Lindley, C M, Sawyer, W T, Macik, B G, Lusher, J, Harrison, J F, Baird-Cox, K, Birch, K, Glazer, S, Roberts, H R

“…To evaluate the pharmacokinetics and pharmacodynamics of recombinant activated factor VII (rFVIIa). Single-dose pharmacokinetics of three dose levels (17.5,…”
Get more information

Evaluation of the Contribution of Cytochrome P450 3A4 to Human Liver Microsomal Bupropion Hydroxylation by FAUCETTE, Stephanie R, HAWKE, Roy L, SHORD, Stacy S, LECLUYSE, Edward L, LINDLEY, Celeste M

“…The purpose of this investigation was to evaluate the role of cytochrome P450 (CYP) 3A4 in human liver microsomal bupropion (BUP) hydroxylation. Across the BUP…”
Get full text

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies by Orlowski, Robert Z., Voorhees, Peter M., Garcia, Reynaldo A., Hall, Melissa D., Kudrik, Fred J., Allred, Tammy, Johri, Anandhi R., Jones, Paul E., Ivanova, Anastasia, Van Deventer, Hendrik W., Gabriel, Don A., Shea, Thomas C., Mitchell, Beverly S., Adams, Julian, Esseltine, Dixie-Lee, Trehu, Elizabeth G., Green, Marie, Lehman, Mary Jo, Natoli, Susan, Collins, Jason M., Lindley, Celeste M., Dees, E.Claire

“…Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in vivo. We therefore sought to…”
Get full text

The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans by Ilic, Katarina, Hawke, Roy L, Thirumaran, Ranjit K, Schuetz, Erin G, Hull, J Heyward, Kashuba, Angela D M, Stewart, Paul W, Lindley, Celeste M, Chen, Mei-Ling

“…The effects of sex, ethnicity, and genetic polymorphism on hepatic CYP2B6 (cytochrome P450 2B6) expression and activity were previously demonstrated in vitro…”
Get full text

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors by Dees, E. Claire, O’Neil, Bert H., Lindley, Celeste M., Collichio, Frances, Carey, Lisa A., Collins, Jason, Riordan, William J., Ivanova, Anastasia, Esseltine, Dixie, Orlowski, Robert Z.

“…Purpose Pre-clinical studies combining the proteasome inhibitor bortezomib with anthracyclines have shown enhanced anti-tumor activity. We conducted a phase I…”
Get full text

Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B by Liles, D, Landen, C N, Monroe, D M, Lindley, C M, Read, M S, Roberts, H R, Brinkhous, K M

“…Current therapy for hemophilia B requires large intravenous doses of factor IX (F.IX) given in the clinic or at home. Although home therapy is possible for…”
Get more information

Patient-Specific Factors Affecting Patient-Controlled Analgesia Dosing by Glasson, Joel C., Sawyer, William T., Lindley, Celeste M., Ginsberg, Brian

“…A study was conducted to evaluate the effect of characteristics patients' gender, age, weight, height, and body surface area, as well as the concurrent or…”
Get full text

Granulocyte colony-stimulating factor use in cancer patients by Baker, J, McCune, JS, Harvey RD, , 3rd, Bonsignore, C, Lindley, CM

“…OBJECTIVE: To conduct a retrospective drug utilization evaluation comparing the use of granulocyte colony-stimulating factor (G-CSF) at a university medical…”
Get full text

Evaluation of Outcomes in Converting from Intravenous Ondansetron to Oral Granisetron: An Observational Study by McCune, Jeannine S, Oertel, Maryann D, Pfeifer, Dennis, Houston, Shelly A, Bingham, Andrea, Sawyer, William T, Lindley, Celeste M

“…OBJECTIVE: To describe a systematic evaluation of the outcomes associated with revising institutional guidelines for the prevention of acute…”
Get full text

Role of angiotensin II and vasopressin in cisplatin-induced emesis by Cubeddu, L X, Lindley, C M, Wetsel, W, Carl, P L, Negro-Vilar, A

“…Cisplatin-containing chemotherapy regimens are known to produce intense nausea and vomiting. Angiotensin II (AII) and vasopressin (AVP) have been shown to have…”
Get more information

Narcotic analgesics. Clinical pharmacology and therapeutics by Lindley, C M, Dalton, J A, Fields, S M

“…Nurses often are responsible for administering narcotic analgesics to patients with pain due to cancer or the treatment of cancer. Because of frequent use of…”
Get more information

ASHP therapeutic position statement on the safe use of oral nonprescription analgesics by Lindley, Celeste M.

Get full text

Cancer Pain Survey: Patient-Centered Issues in Control by Thomason, Tracy E., McCune, Jeannine S., Bernard, Stephen A., Winer, Eric P., Tremont, Steve, Lindley, Celeste M.

“…It is widely believed that patients’ reluctance to report pain and adhere to treatment recommendations are significant barriers to cancer pain control…”
Get full text

Coagulation products and their uses by Shord, SS, Lindley, CM

“…The indications, pharmacokinetics, and therapeutic guidelines for available coagulation products are reviewed. Patients with hemophilia, von Willebrand's…”
Get full text

Cancer Pain Survey by Thomason, Tracy E., McCune, Jeannine S., Bernard, Stephen A., Winer, Eric P., Tremont, Steve, Lindley, Celeste M.

Get full text

Pharmacy-perceived barriers to cancer pain control: results of the North Carolina Cancer Pain Initiative Pharmacist Survey by Krick, S E, Lindley, C M, Bennett, M

“…To assess pharmacists' knowledge, attitudes, and beliefs regarding the use of narcotics in cancer pain management, identify pharmacist counseling activities…”
Get more information

Assessment of pain and patterns of analgesic use in hospice patients by Morgan, A E, Lindley, C M, Berry, J I

“…The purpose of this study is to describe patterns of pain, analgesic use, barriers to pain control, and various aspects of lifestyle affected by pain in…”
Get more information

Methotrexate elimination in a patient with an orthotopic neobladder with and without a urethral catheter by Wire, P D, Dupuis, R E, Mohler, J L, Bernard, S A, Lindley, C M

“…Placement of a urethral catheter has been recommended to ensure adequate methotrexate elimination in patients with a neobladder; however, the need for this and…”
Get more information